ANNAIDA is a groundbreaking startup operating in the biotechnology sector. The company has developed a novel, non-invasive technology that allows for the analysis of the chemistry within microscopic life forms, while preserving their full integrity. This technology is primarily used to understand the metabolic fingerprint of cellular life, which can range from embryos to stem-cell organoids.

ANNAIDA's primary product is the EmbryoSpin device, which utilizes non-invasive Magnetic Resonance Spectroscopy (MRS) technology. MRS is a type of imaging that provides detailed information about the chemical composition of tissues, which can be used to detect disease or monitor treatment. ANNAIDA has miniaturized this technology to a micro scale, allowing researchers to easily characterize cellular metabolism.

The company's technology is beneficial to a wide range of clients, including researchers in universities and corporate labs, as well as professionals in assisted reproductive therapy (ART). In the field of ART, the EmbryoSpin device can be used to improve embryo selection, thereby enhancing patient outcomes. Furthermore, the technology can be used to conduct research in toxicology and drug discovery, making these processes more effective.

ANNAIDA's business model revolves around the sale of their EmbryoSpin device and the provision of related services. The company generates revenue through the sale of these devices to research institutions and fertility clinics, as well as through the provision of services related to the use of their technology.

Keywords: Biotechnology, Non-invasive technology, Cellular life, Metabolic fingerprint, EmbryoSpin device, Magnetic Resonance Spectroscopy, Research, Assisted Reproductive Therapy, Toxicology, Drug discovery.